xylasol 20 mg/ml, solution for injection
cp-pharma handelsgesellschaft mbh - xylazin hydrochloride - solution for injection - 20 mg/ml - neurological preparations - bovine canine equine - food feline
inomax
biomedical strategy consultants pte ltd - nitric oxide - gas - 800ppm
inomax
linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.
xylapan 20 mg/ml solution for injection
vetoquinol uk limited - xylazine - solution for injection - 20 milligram(s)/millilitre - xylazine - cats, cattle, dogs, horses - neurological preparations
clonidine transdermal system, usp
viatris limited - clonidine 2.52mg equivalent to 0.1 mg/24hr - transdermal patch - 0.1 mg/24h - active: clonidine 2.52mg equivalent to 0.1 mg/24hr excipient: adhesive 8400e/000 colloidal silicon dioxide durotak 87-613a ethylenevinylacetate copolymer heptane light liquid paraffin no tox ink brown- fgn4476 - clonidine transdermal system usp is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.
clonidine transdermal system, usp
viatris limited - clonidine 5.04mg equivalent to 0.2 mg/24hr - transdermal patch - 0.2 mg/24h - active: clonidine 5.04mg equivalent to 0.2 mg/24hr excipient: adhesive 8400e/000 colloidal silicon dioxide durotak 87-613a ethylenevinylacetate copolymer heptane light liquid paraffin no tox ink brown- fgn4476 - clonidine transdermal system usp is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.
clonidine transdermal system, usp
viatris limited - clonidine 7.56mg equivalent to 0.3mg/24hr - transdermal patch - 0.3 mg/24h - active: clonidine 7.56mg equivalent to 0.3mg/24hr excipient: adhesive 8400e/000 colloidal silicon dioxide durotak 87-613a ethylenevinylacetate copolymer heptane light liquid paraffin no tox ink brown- fgn4476 - clonidine transdermal system usp is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.
akorn anased 2% injection
akorn animal health nz ltd - xylazine present as xylazine hydrochloride - xylazine present as xylazine hydrochloride 20 g/litre - analgesic
calezine 20
dechra veterinary products nz limited - xylazine - xylazine 20 g/litre - sedative
iopidine solution
essential pharma switzerland gmbh - apraclonidine (apraclonidine hydrochloride) - solution - 1% - apraclonidine (apraclonidine hydrochloride) 1% - eent drugs, miscellaneous